Predictive Diagnostics - Worldwide Market Outlook Report, 2019: Growth Drivers, Trends and Issues
DUBLIN, April 4, 2019 /PRNewswire/ -- The "Predictive Diagnostics - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.
This report analyzes the worldwide markets for Predictive Diagnostics in US$ Thousand.
The report profiles 47 companies including many key and niche players such as:
- Abbott Molecular (USA)
- Almac Group Ltd. (Ireland)
- Ambry Genetics Corporation (USA)
- BioGenex (USA)
- Epistem Ltd. (UK)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Genomic Health, Inc. (USA)
- MDxHEALTH, Inc. (USA)
- Myriad Genetics, Inc. (USA)
- OPKO Health, Inc. (USA)
- Prometheus Laboratories Inc. (USA)
- Proteomics International Laboratories Ltd (Australia)
- QIAGEN N.V. (The Netherlands)
Key Topics Covered
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
2. INDUSTRY OVERVIEW
A Curtain Raiser
Predictive Diagnostics - A Key Segment of Genetic Testing
Outlook for Predictive Diagnostics Market
Prospects for Predictive Genetic Diagnostics Grow Brighter
Oncology: A Key Growth Driver for Predictive Diagnostics
Genes and Associated Cancers/Tumors
Predictive Diagnostics - Crucial for Breast Cancer Management
Inherited Breast Cancer - An Important End-use Market for Predictive Diagnostics
About BRCA1 and BRCA2
Breast Cancer Gene Testing Market to Expand Strongly
Myriad Genetics-The Unquestioned Leader in Breast Cancer Testing
The First FDA-Approved DTC Breast Cancer Genetic Assay
Limitations of Breast Cancer Screening
Growing Popularity of Multi-gene Panels in Clinical Cancer Genetics
Clinical Characteristics of Moderate-High Penetrance Genes Other than BRCA1/2
Challenges Associated with Multigene-Panel Testing
Next-Generation Sequencing - A Giant Leap in Genome Sequencing
Genes Included in NGS Panels
Increasing Incidence of Colorectal Cancer in <_0 age="age" group_="group_" a="a" business="business" case="case" for="for" predictive="predictive" />Growing Number of Colorectal Cancer Risk Population with Lynch Syndrome
Genes Associated with Inherited Risk of Colorectal Cancer
Launch of PromarkerD: Hope for Early Diagnosis of Diabetic Kidney Disease
What is PromarkerD?
Patents for PromarkerD
3. SELECT PREDICTIVE DIAGNOSTIC TESTS/ASSAYS AVAILABLE
The BRACAnalysis Assay
Oncotype Dx Prostate Cancer Assay
Myrisk Hereditary Cancer Panel
EndoPredict
LifeKit Predict
Prolaris Genetic Test
SelectMDx
Breast Cancer Index (BCI) Test
The PancraGEN Assay
Proove Opioid Response Assay
VeriStrat Test
BRAF Mutation Detection Assay
Oncotype Dx Colon Cancer Test
ColoPrint 18-Gene Colon Cancer Recurrence Test
ROMA Assay
Panexia Assay
CytoScan Dx Assay
Oncotype Dx Breast Cancer Assay
4. GROWTH DRIVERS, MARKET TRENDS AND ISSUES
Rising Incidence and Prevalence of CDDs: A Major Growth Driver
Increasing Cancer Disease Burden Drives the Demand for Predictive Diagnostics
Incidence of Neurodegenerative Diseases Increasing
Alzheimer's Disease
Huntington's Disease
Quick Facts on the Global Prevalence of Huntington's Disease
Parkinson's Disease
Ballooning Global Population Offers Significant Growth Opportunities
Predictive Diagnostics Enable Higher Life Expectancy
Widening of Insurance Coverage for Hereditary Cancer Testing
Discovery of Novel Biomarkers - Crucial to Predictive Diagnostics
Genomic Research Remains Confined to Fundamental Research
Unresolved Issues Hamper Widespread Implementation of Genetic Testing for Monogenetic Disease
Dearth of Genetic Counselors - A Major Hurdle for the Predictive Genetic Testing
Framework for Validation, Regulation, and Ethical Issues - The Need of the Hour
5. PRODUCT OVERVIEW
Introduction
Underlying Principles of Predictive Diagnostics
Predictive Diagnostics Vis-a-vis Conventional Testing
Characteristics of an Effective Predictive Diagnostic Test
Applications of Predictive Diagnostics
Pre-Symptomatic
Predisposition Testing
Cancer Testing
Carrier Identification
Steps in Genetic Testing Process
Limitations
Risks and Other Limitations of Genetic Testing
Select Diseases Identified Using Predictive Diagnostics
Cystic Fibrosis
Breast and Ovarian Cancer (BRCA)
Alzheimer's Disease
Colorectal Cancer
Hemochromatosis (HH)
Huntington's Disease (HD)
Costs of Select Tests
Medical Ethics Surrounding Predictive Diagnostics
6. COMPETITIVE LANDSCAPE
6.1 Focus on Select Key Players
6.2 Product Introductions
BaseHealth Introduces First Predictive Analytics Platform
Predictive Diagnostics Introduces Endometriosis Risk Test
Proteomics International Enters into Licensing Agreement with PrismHealthDx for the Launch of PromarkerD Predictive Test in the US
SQI Diagnostics and Predictive Health Diagnostics Introduces Revolutionary Predictive Cardiac Test
QIAGEN Introduces Predictive Therascreen PITX2 Test in Europe
Proteomics International Laboratories Announces the Official Launch of Predictive diagnostic test, PromarkerD
MDxHealth Introduces AssureMDx for Bladder Cancer Liquid Biopsy Test
LabCorp Introduces Sera Prognostics' PreTRM Test
Proteomics International Laboratories presents an update on commercialisation progress for the PromarkerD test
6.3 Recent Industry Activity
FDA Authorizes First Direct-to-Consumer Genetic Test from 23andMe for Cancer Risk
Proteomics International Agrees with PrismHealthDx for Launching PromarkerD predictive test in the US
Proteomics International Announces the Availability of PromarkerD kit version for Imminent Commercial Release
Proteomics International Collaborates with Janssen to Evaluate PromarkerD Kidney Disease Test
Predictive Technology Group Completes the Acquisition of Inception Dx
Epistem Announces the Completion of Management Buyout
MDxHealth Enters into Worldwide Licencing Agreement with Philips for Prognostic Prostate Cancer Biomarker
Konica Minolta Completes the Acquisition of U.S.-based Ambry Genetics
Color Genomics Receives Investments from High-Profile Investors
SQI Diagnostics Sells Automated Sqidlite Platform to Predictive Cardiac Customer
MDxHealth Associates with Ferrer to Distribute SelectMDx in Spain
Prescient Medicine Acquires PGxL Laboratories
7. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 47 (including Divisions/Subsidiaries - 48)
- The United States (27)
- Canada (1)
- Europe (15)
- Germany (4)
- The United Kingdom (6)
- Spain (1)
- Rest of Europe (4)
- Asia-Pacific (Excluding Japan) (4)
- Middle East (1)
For more information about this report visit https://www.researchandmarkets.com/research/mxr5zw/predictive?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article